Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BetaLogics' in vitro beta cells

BetaLogics Venture and The University of British Columbia have developed an in vitro protocol to generate mature insulin-producing pancreatic b-like cells from human pluripotent stem cells.1 The findings mark a major milestone for the development of new cell-based therapies for diabetes.

Harvard University researchers have separately described an in vitro protocol for generating similar cells but were unable to provide commentary in time for publication.2

BetaLogics is a venture division of Johnson & Johnson's Janssen R&D LLC unit. The division's goal is to develop and commercialize stem cell products for diabetes treatment.

The BetaLogics-UBC team and other independent research groups have previously described protocols to differentiate human pluripotent stem cells into pancreatic progenitor cells in vitro. 3-7 However, these cells still need to be matured into the desired insulin-producing cells in vivo. The BetaLogics-UBC group has previously reported that diabetic mice

Read the full 1381 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers